Recently, we have shown that administration of 2G TKIs, such as nilotinib and dasatinib, can overcome high CIP2A and prevent disease progression.5, 27 However, this is not without worrying side effects, as dasatinib has a 25% risk of pleural effusion within ~3 years and nilotinib therapy is associated with hyperglycemia in some patients and a dose-related (8–10%) risk of myocardial infarction, cerebrovascular event or peripheral arterial occlusive event by 6 years.30, 31 This necessitates research into possible alternate therapeutic strategies. The gene discussed is CIP2A; the disease is Hyperglycemia.